Cargando…

Comparison between trabectedin and doxorubicin in soft-tissue sarcomas-reply letter

Detalles Bibliográficos
Autores principales:	Dang, Jing-Yi, Fu, Jun, Zhang, Zhao, Liu, Dong, Cheng, Debing, Fan, Hongbin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073790/ https://www.ncbi.nlm.nih.gov/pubmed/35530938 http://dx.doi.org/10.21037/atm-2022-1

Ejemplares similares

Comparison between trabectedin and doxorubicin in soft-tissue sarcomas: a systematic review and meta-analysis
por: Dang, Jingyi, et al.
Publicado: (2021)

Trabectedin in Soft Tissue Sarcomas
por: Petek, Bradley J., et al.
Publicado: (2015)

Trabectedin for soft tissue sarcoma
Publicado: (2021)

Do patients with soft-tissue sarcomas treated with trabectedin have better clinical effects and a longer survival time than those treated with doxorubicin?
por: Wu, Jiangfeng, et al.
Publicado: (2022)

The Role of Trabectedin in Soft Tissue Sarcoma
por: Nakamura, Tomoki, et al.
Publicado: (2022)

Role of trabectedin in the treatment of soft tissue sarcoma
por: Christinat, Alexandre, et al.
Publicado: (2009)

The value of trabectedin in the treatment of soft tissue sarcoma
por: Nakamura, Tomoki, et al.
Publicado: (2016)

Trabectedin and its potential in the treatment of soft tissue sarcoma
por: Cassier, Philippe A, et al.
Publicado: (2008)

Trabectedin for advanced soft tissue sarcomas: optimizing use
por: Reid, Alison, et al.
Publicado: (2014)

Pharmacometabolomics of trabectedin in metastatic soft tissue sarcoma patients
por: Corona, Giuseppe, et al.
Publicado: (2023)

Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age
por: HOICZYK, MATHIAS, et al.
Publicado: (2013)

Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives
por: Gordon, Erlinda M., et al.
Publicado: (2016)

Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas
por: Recine, Federica, et al.
Publicado: (2017)

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
por: Laroche, Audrey, et al.
Publicado: (2017)

Radiosensitizing Effect of Trabectedin on Human Soft Tissue Sarcoma Cells
por: Loi, Mauro, et al.
Publicado: (2022)

Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma
por: Thornton, Katherine A
Publicado: (2010)

Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma
por: De Sanctis, Rita, et al.
Publicado: (2015)

Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin
por: Desar, Ingrid M E, et al.
Publicado: (2016)

Trabectedin for Metastatic Soft Tissue Sarcoma: A Retrospective Single Center Analysis
por: Schmitt, Thomas, et al.
Publicado: (2010)

Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma [Corrigendum]
Publicado: (2016)

BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients
por: Laroche-Clary, A, et al.
Publicado: (2015)

A Prolonged Response and Characteristics of Trabectedin Treatment of Metastatic Soft Tissue Sarcoma
por: Reuben, Daniel Y.
Publicado: (2021)

Trabectedin Cardiotoxicity in Soft Tissue Sarcoma: A Case Series and Clinical Insights
por: Gent, David G., et al.
Publicado: (2022)

Reply to Letter to the Editor: “Can ARNI Prevent Doxorubicin-Induced Cardiotoxicity?”
por: Dindaş, Ferhat, et al.
Publicado: (2022)

The Use of Positron Emission Tomography in Soft Tissue Sarcoma Patients under Therapy with Trabectedin
por: Kasper, Bernd, et al.
Publicado: (2009)

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
por: Kawai, Akira, et al.
Publicado: (2017)

Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma
por: Maillard, Maud, et al.
Publicado: (2020)

Reply: Comment on ‘Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients'
por: Szkandera, J, et al.
Publicado: (2013)

Cost Effectiveness of First-Line Treatment with Doxorubicin/Ifosfamide Compared to Trabectedin Monotherapy in the Management of Advanced Soft Tissue Sarcoma in Italy, Spain, and Sweden
por: Guest, Julian F., et al.
Publicado: (2013)

Trabectedin in the treatment of metastatic soft tissue sarcoma: cost-effectiveness, cost-utility and value of information
por: Soini, E. J. O., et al.
Publicado: (2011)

Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study
por: Angarita, Fernando A., et al.
Publicado: (2016)

Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients
por: Verboom, Michiel C., et al.
Publicado: (2019)

Trabectedin Drug Holiday and Rechallenge in Soft Tissue Sarcomas: Report of 4 Cases and Literature Review
por: Pierantoni, Francesco, et al.
Publicado: (2019)

Reply to the letter
por: Hirata, Naoyuki, et al.
Publicado: (2020)

Reply to Letter:
por: Dillinger, Jean-Guillaume, et al.
Publicado: (2020)

Reply to the letter
por: Hotta, Kunihisa
Publicado: (2020)

Reply to letter
por: Tam, Wilson, et al.
Publicado: (2021)

Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center
por: Hindi, Nadia, et al.
Publicado: (2020)

Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group
por: Palmerini, Emanuela, et al.
Publicado: (2021)

Reply to letter to editor
por: Sayanlar, Jennifer, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ilhvhu8tkjgquf3iub186icmi3